The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Zynlonta Market During The Forecast Period 2026–2030?

The historical growth can be linked to the increasing occurrence of hematological malignancies, the escalating failure rates of conventional chemotherapy, the proliferation of oncology specialty centers, enhanced diagnostic capabilities for lymphoma subtypes, and the expanding clinical integration of ADC therapies.

Future growth in the forecast period is expected due to the ongoing advancement of next-generation antibody-drug conjugates, the escalating demand for individualized cancer care, the broadening of targeted oncology drug pipelines, increasing financial commitments to biologic cancer medications, and the expanded application of combination cancer treatments. Key developments anticipated during this period encompass the wider acceptance of antibody-drug conjugate therapies, a rise in targeted treatments for B-cell lymphomas, an increased focus on precision oncology drugs, the expansion of hospital-based oncology infusion services, and a heightened emphasis on therapies for relapsed and refractory cancers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20435&type=smp

Which Economic Or Industry Drivers Are Impacting The Zynlonta Market?

An anticipated increase in lymphoma cases is projected to boost the expansion of the zynlonta market. Lymphomas are a category of cancers that develop within the lymphatic system, primarily impacting lymphocytes, which are a type of white blood cell present in areas such as lymph nodes, the spleen, bone marrow, and other lymphatic tissues. This growing occurrence of lymphomas is linked to several elements, including an aging demographic, suppressed immune systems, environmental influences, viral infections, genetic susceptibilities, and certain lifestyle decisions. Zynlonta serves as a focused treatment for relapsed or refractory large B-cell lymphoma (LBCL), operating by directly administering a chemotherapy agent to malignant B cells, thereby eliminating them. For example, the American Cancer Society, a US-based non-profit organization, reported an estimated rise in new lymphoma cancer cases from 89,010 in 2022 to 89,380 in 2023. Consequently, the increasing prevalence of lymphomas is a significant factor driving the expansion of the zynlonta market.

What Market Segments Are Evaluated Within The Zynlonta Market?

The zynlonta market covered in this report is segmented –

1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma, DLBCL Arising From Follicular Lymphoma

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Adult Patients, Geriatric Patients

What Industry Trends Are Redefining The Zynlonta Market?

A key trend within the zynlonta market focuses on developing innovative therapeutic approaches, such as combination therapies, to improve treatment efficacy and enhance patient outcomes in cancer care. Combination therapies involve utilizing two or more treatments, including various drugs or therapeutic methods, to boost overall therapeutic effectiveness and address multiple dimensions of a disease. For example, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company specializing in the creation of antibody-drug conjugates (ADCs) for treating hematological malignancies and solid tumors, provided updates on its LOTIS-7 clinical trial. This trial is evaluating Zynlonta (loncastuximab tesirine-lpyl) when combined with bispecific antibodies like glofitamab or mosunetuzumab. The trial aims to provide treatment for heavily pretreated patients suffering from relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Who Are The Top Market Participants Influencing The Zynlonta Market?

Major companies operating in the zynlonta market are ADC Therapeutics SA, Avid Bioservices Inc

Read the full zynlonta market report here:

https://www.thebusinessresearchcompany.com/report/zynlonta-global-market-report

What Are The Top-Performing Regions Within The Zynlonta Market?

North America was the largest region in the zynlonta market in 2025. The regions covered in the zynlonta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Zynlonta Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20435&type=smp

Browse Through More Reports Similar to the Global Zynlonta Market 2026, By The Business Research Company

Zinc Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-global-market-report

Zinc Oxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-oxide-global-market-report

Zinc Citrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-citrate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model